Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 7:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–64 of 64 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Cortisol Excess Clear all

Conditions: Hyperaldosteronism, Hypercortisolism, Cushing s Syndrome
Interventions: [68Ga]Ga-PentixaFor; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cushing's Syndrome
Interventions: Not listed
Lead sponsor: National Center for Research Resources (NCRR); NIH
Eligibility: 0 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 1999
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Cushing Syndrome, Neoplasms
Interventions: Dabigatran Etexilate, Relacorilant; Drug
Lead sponsor: Corcept Therapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Cushing's Syndrome
Interventions: Treatment of Cushing's; Procedure
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Cushing's Syndrome
Interventions: Cushing's syndrome confirmation; Drug
Lead sponsor: Corcept Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 3
States / cities: Escondido, California • Hollywood, Florida • San Antonio, Texas

Conditions: Endogenous Cushing's Syndrome
Interventions: Osilodrostat; Drug
Lead sponsor: RECORDATI GROUP; Industry
Eligibility: 18 Years and older
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 15
States / cities: Phoenix, Arizona • Atlanta, Georgia • Chicago, Illinois + 11 more

Conditions: Mild Autonomous Cortisol Secretion, Autonomous Cortisol Secretion (ACS)
Interventions: Osilodrostat 1 MG; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Cushing Syndrome, Endocrine Disease
Interventions: Pentetreotide, 18F-DOPA, CT scan, MRI, 18-FDG; Drug · Device
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 18 Years to 90 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Adrenal Gland Hyperfunction, Cardiovascular Disease, Involutional Depression
Interventions: Not listed
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 21 Years to 55 Years
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1999 – 2007
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hyperandrogenemia, Obesity, Polycystic Ovary Syndrome
Interventions: Hydrocortisone, dexamethasone, Cosyntropin, rhCG; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 7 Years to 16 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Subclinical Hypercortisolism, Cushing Syndrome, Adrenal Neoplasm
Interventions: Adrenalectomy, Observation; Procedure · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cushing's Syndrome
Interventions: osilodrostat; Drug
Lead sponsor: RECORDATI GROUP; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 10
States / cities: Aurora, Colorado • Atlanta, Georgia • Chicago, Illinois + 6 more

Conditions: Cushing's Syndrome
Interventions: CORT125134; Drug
Lead sponsor: Corcept Therapeutics; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 12
States / cities: Laguna Hills, California • Aurora, Colorado • Fort Lauderdale, Florida + 9 more

Conditions: Endogenous Cushing's Syndrome
Interventions: Levoketoconazole, Placebo; Drug
Lead sponsor: Cortendo AB; Industry
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 13
States / cities: Los Angeles, California • Fort Lauderdale, Florida • Atlanta, Georgia + 7 more

Conditions: Cushing's Disease, Cushing's Syndrome
Interventions: Mifepristone; Drug
Lead sponsor: Corcept Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 5
States / cities: Hollywood, Florida • Baltimore, Maryland • Ann Arbor, Michigan + 2 more

Conditions: Cushing Syndrome
Interventions: LCI699; Drug
Lead sponsor: RECORDATI GROUP; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 5
States / cities: San Francisco, California • Cape Coral, Florida • Chicago, Illinois + 2 more

Search by objective public record fields.

Evaluating the Functional Status of the Adrenal Glands With [68Ga]Ga-PentixaFor in Hyperaldosteronism and Hypercortisolism

Study of Hypercortisolism in Cushing's Syndrome and Stress-Induced Pseudo-Cushing's Syndrome

Effect of Relacorilant on the Pharmacokinetics of the Sensitive P-glycoprotein Substrate Dabigatran Etexilate in Healthy Participants

Novel Mediators of the Lipodystrophy and Metabolic Consequences of Cushing's Disease

A Study to Confirm Recurrent or Persistent Cushing's Syndrome in Patients With Signs or Symptoms of Hypercortisolemia

Non-interventional Study on Osilodrostat in Patients With Endogenous Cushing's Syndrome

Impact of 1 mg Osilodrostat Therapy on Mild Autonomous Cortisol Secretion (MACS)

New Imaging Techniques in the Evaluation of Patients With Ectopic Cushing Syndrome

Heart Disease Risk Factors in Major Depression

Effect of Longer-term Adrenal Suppression Using Low Dose Hydrocortisone on Androgen Overproduction

Study of Adrenalectomy Versus Observation for Subclinical Hypercortisolism

Roll-over Study in Patients With Endogenous Cushing's Syndrome for LCI699

Study to Evaluate CORT125134 in Participants With Cushing's Syndrome

A Study to Assess the Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing's Syndrome.

Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome

Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's Syndrome